Abstract Background and Aim Potassium‐competitive acid blocker (PCAB) is a recent
alternative to proton pump inhibitor (PPI) for potent acid suppression. The current systematic …

Aim Previous studies on the association between proton pump inhibitor (PPI) intake and the
increased risk of dementia has shown discrepancies in their conclusions. We aimed to …

New concepts and drugs have revolutionized medical treatment for cancers. These drugs,
which are very expensive and usually well tolerated, have dramatically improved cancer …

Abstract Background and Aims Observational research has indicated that proton pump
inhibitors (PPIs) might increase the long-term risk of cardiovascular events. This study …

Proton pump inhibitors (PPIs) are commonly used for gastric acid-related disorders, but their
safety profile and risk stratification for high-burden diseases need further investigation …

Abstract Background and Aims Acid‐suppressive drugs (ASDs) are widely used in many
gastric acid‐associated diseases. Nocturnal acid breakthrough has been a common …

Introduction Proton pump inhibitor (PPI) is the mainstay therapy for the maintenance of
healed erosive esophagitis (EE). It is unknown whether potassium‐competitive acid blockers …

Objectives To perform a comprehensive quantitative and qualitative analysis of the findings
from previously published meta-analyses and to assess existing biases. Data/Sources A …

Proton-pump inhibitors (PPIs) are the most administered first-line treatment for eosinophilic
esophagitis (EoE). However, only around half of EoE patients respond histologically to a …

Introduction Severe acute respiratory syndrome coronavirus 2 is a viral respiratory infection
that can cause systemic disorders and lead to death, particularly in older people. Proton …